Henry Brem was appointed Director of Galectin Therapeutics Inc. As of November 14, 2026, Galectin Therapeutics Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 12, 2026 to March 17, 2026, naming 1 appointment and 1 departure (Form 8-K, March 17, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Galectin Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Galectin Therapeutics Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-12 to 2026-03-17. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Galectin Therapeutics Inc files it.
Also on the record for Galectin Therapeutics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 4, 2026 | Stake report, Schedule 13D/A, by Richard E. Uihlein | 49.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Galectin Therapeutics Inc now and the warning signs.
Free to see. No signup.
Watch Galectin Therapeutics Inc
Get an email when Galectin Therapeutics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Galectin Therapeutics Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Galectin Therapeutics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Galectin Therapeutics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-03-17 | In | Director | 8-K, 2026-03-17 | ||
| 2026-01-12 | Out | 8-K, 2026-01-12 |
Why did they leave? What the filings say
For each named departure below, the sentence from the company's own filing that gives a reason, word for word. Where a filing gives none, it says so here; nothing is inferred.
- Marc Rubin (filed 2026-01-12):
Mr. Rubin's resignation is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices.
Who leads Galectin Therapeutics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Henry Brem, appointed (filed 2026-03-17).
New leaders reset buying decisions — get the Full Report on Galectin Therapeutics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Galectin Therapeutics Inc, with the record behind each one.
Find candidates like Director at Galectin Therapeutics IncEvery change, in the filing's words
Appointed: Henry Brem, Director
On March 12, 2026, the Board of Directors of Galectin Therapeutics Inc. (the "Company") appointed Dr. Henry Brem to serve as a member of the Board of Directors, effective immediately.
- Dr. Brem will receive compensation for his service on the Board in accordance with the Company's standard non-employee director compensation program, which is described in the Company's most recent proxy statement filed with the Securities and Exchange Commission.
- Dr. Henry Brem, a director since 2026, is an internationally recognized neurosurgeon-scientist and leader in translational medicine.
- He serves as the Henry Brem Professor of Neurosurgery at Johns Hopkins University and previously served from 2000 until 2025 as Director of the Department of Neurosurgery and Neurosurgeon-in-Chief at The Johns Hopkins Medical Institutions.
- He is also Co-Director of the Brain Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.
- Dr. Brem has helped transform neurosurgical oncology through the development of image-guided surgical techniques and localized drug delivery systems, including Gliadel wafers for brain tumors.
- He has published more than 416 peer-reviewed papers, holds multiple patents, and has been continuously funded by the NIH for over four decades.
- He is a member of the National Academy of Medicine and has received numerous honors recognizing his contributions to clinical excellence and translational research.
- Dr. Brem has served as director for multiple private and public companies.
Departing: Marc Rubin
On January 10, 2026, Marc Rubin resigned from the Board of Directors of Galectin Therapeutics, Inc. (the "Company").
Tools for this story
Each opens in a new tab, filled in for Galectin Therapeutics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
